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Abstract
Background: Benign Prostatic Hypertrophy (BPH) is said to aﬀect at least a third of men over 60. However, the
literature contains fewer than 200 reports of prostates over 200g in mass - Giant Prostatic Hypertrophy (GPH).
Nephrogenic adenomas are benign lesions of the urinary tract that are believed to represent the local proliferation of
shed renal tubular cells implanting at sites of urothelial injury.
Case presentation: We present the ﬁrst case in the literature of these two rare pathologies co-existing in the same
patient and the successful management and 36-month follow-up of the patient’s symptoms with minimally invasive
therapy, including the still-uncommon selective prostatic artery embolisation. We also brieﬂy discuss the role of PAX2
in injured renal tissues and nephrogenic adenomas.
Conclusions: Symptomatic Giant Prostatic Hypertrophy (GPH) can be successfully managed with a combination of
serial TURPs, 5α-reductase inhibition and selective prostatic artery embolisation (SPAE).
Background
Giant prostatic hypertrophy (GPH) is the benign hyper-
trophy of the prostate gland to a mass exceeding 200g.
The condition was was originally described by Blanchot in
1952 [1] and has appeared in the English-language litera-
ture fewer than 50 times since, although more cases have
been reported in the Asian literature (84 in the Chinese [2]
and 33 in the Japanese [3]). GPH commonly presents with
obstructive lower urinary tract symptoms and hæmaturia.
Owing to the size of the gland, deﬁnitive treatment usu-
ally requires suprapubic prostatectomy, although a case
of successful management via 3 separate transurethral
resections has been described [4].
Nephrogenic adenoma is a separate disease entity, ﬁrst
described by Davis in 1949 [5] and most commonly com-
prising small lesions (<1cm) located within the bladder
(80%) [6] and histologically resembling distal renal tubules
[7]. Whilst nephrogenic adenomas are benign, they can
however mimic prostatic adenocarcinoma when located
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in the prostatic urethra, unless diﬀerentiated by immunos-
taining [6]. For lesions causing obstruction or hæma-
turia, endoscopic management is usually eﬀective with the
caveat that they can recur in up to 90% of cases [8].
We present the case of a patient who suﬀered years
of irritative lower urinary tract symptoms (LUTS) and
hæmaturia from a 460g prostate inﬁltrated with nephro-
genic adenoma but elected not to undergo suprapubic
prostatectomy. He was successfully managed by serial
TURPs and selective prostatic artery embolisation (SPAE),
and has remained symptom free for more than 36 months
since.
We also discuss GPH and nephrogenic adenoma, and
review the literature surrounding SPAE for intractable
hæmaturia of prostatic origin.
Case presentation
Initial presentation
In April of 2001, a 62 year old man with a past history
of mild hypertension, hyperthyroidism and vitiligo pre-
sented to our department via his General Practitioner
(GP) with irritative LUTS of 2–3× nocturia, daytime
frequency (once every 1–2 hours) and a PSA of 4.6 ng/mL.
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Physical examination revealed an otherwise healthy
patient. Digital rectal examination found the prostate
to be smoothly enlarged and symmetrical. Qmax at
this time was 14.4mL/sec. Transrectal biopsy of the
gland was entirely benign. In addition to continuing
the prazosin 2mg BD prescribed for his hyperten-
sion, the patient was given a trial period of toltero-
dine XL 4mg OD and asked to return for review after
6 months.
At this review, the patient’s PSA had fallen to 3ng/mL
and he described symptomatic improvement with toltero-
dine. He was therefore discharged back to the care of his
GP.
Unfortunately, the patient’s irritative symptoms
returned despite previous pharmacological success, with
3–4× nocturia, 2–hourly daytime frequency and drib-
bling urge incontinence. He also described hesitancy and
slow ﬂow. No ﬂow testing was performed at this time,
but the patient was oﬀered a cystoscopy under anæsthe-
sia with consent to proceed to a TURP should it prove
necessary.
Rigid cystoscopic examination under spinal anæsthe-
sia revealed a large, highly vascular prostate protruding
into an otherwise normal bladder. Owing to the diﬃ-
cult combination of the vascularity and the prolonged
operation time under spinal anæsthesia, only an esti-
mated 50% of the gland was resected, weighing 35g. The
complicated nature of his resection was evidenced by a
greater than 2 g/dL fall in his hæmoglobin from its pre-
operative level of 12.9 g/dL to 10.6 g/dL. His coagulation
studies were normal. Histology revealed benign prostatic
hyperplasia (BPH) with evidence of minor, focal chronic
inﬂammation.
Just 3 months after this procedure, the patient returned
with the same irritative LUTS of urgency and 2–hourly
daytime frequency but now with suprapubic pain on
micturition as well as intermittent lightly stained frank
hæmaturia. Two mid-stream samples sent by his GP
were negative for infection. An urgent ﬂexible cystoscopic
examination revealed no post-TURP stricturing, but there
was a degree of post-operative bladder reaction and a large
part of his large vascular median lobe remained protrud-
ing into the bladder. His ﬂow rate had also dipped to a
Qmax of 6.8 mL/sec. He was taken oﬀ his tolterodine and
commenced on ﬁnasteride 5mg OD with the caveat that
he may warrant a further TURP to complete the resection
should his symptoms persist. At a review appointment 6
weeks later, the patient elected to continue pharmacolog-
ical management rather than to undergo a further TURP.
His ﬂow rate improved over the next 3 months to reach a
Qmax of 11.3 mL/sec.
Fortunately, for nearly the next 3 years on ﬁnasteride
the patient reported good ﬂow, no frank hæmaturia and
minimal irritative lower urinary tract symptoms. His
Qmax reached 14 mL/sec, and his PSA remained around
1.7–1.8 ng/mL.
Diagnosis of giant prostatic hypertrophy and nephrogenic
adenoma of the prostatic urethra
In June of 2005, the patient returned to his GP with a few
days of frank, heavily stained hæmaturia. A subsequent
trans-abdominal ultrasound in our rapid-access hæma-
turia clinic estimated his prostate volume at 215 cm3
– a dramatic increase from the estimated volume of 70
cm3 at his original TURP. However, there was no evi-
dence of upper tract or outﬂow obstruction with only a
very minimal post-voiding residual (however, no quan-
tiﬁcation was given in the patient notes at the time).
Flexible cystoscopy that day revealed an enlarged, highly
vascular intravesical median lobe of the prostate with an
oozing necrotic mucosal lesion in the prostatic urethra
superﬁcially resembling a transitional cell carcinoma.
Transurethral resection of the mucosal lesion under
general anæsthesia obtained 4 mm of papillary tissue and
6 g of prostate chippings to check for deep extension.
Therapeutic TURP was not considered at this time given
the visual appearance of invasive carcinoma. Indeed, his-
tological examination of the papilliform tissue revealed
small tubules lined by mildly atypical cells focally extend-
ing into muscle, consistent with an adenocarcinoma of
the lamina propria and superﬁcial muscularis. The pro-
static chips revealed only benign glandular and stromal
prostatic tissue with hyperplasia, but no PIN or invasive
malignancy.
However, supplementary immunostaining and reexam-
ination of the suspected adenocarcinoma revealed no
mitoses within the tissue and the ﬁndings were reinter-
preted as those of a benign nephrogenic adenoma of the
prostatic urethra.
Whilst only a small amount of prostatic urethral tis-
sue was taken for diagnostic purposes, this eﬀectively
prevented any further frank hæmaturia for 12 months.
An intermittent period of irritative LUTS were managed
by decreasing the patient’s caﬀeine intake. The patient
continued to take ﬁnasteride 5 mg OD.
In July of 2006 the patient was referred back to our
service with 3 days of frank hæmaturia with clots. By
the time we saw him in clinic he had been bleeding
intermittently for approximately 3 weeks. Fortunately, his
hæmoglobin was within the normal range at 13.4 g/dL,
and again his coagulation studies were normal. Upper
tract imaging was also normal. Given the patient’s previ-
ous history, a further TURP was performed in September
2006 which obtained 60 cm3 of prostate chips. Histology
revealed mainly BPH with a few foreign body granulo-
mata. There was marked proliferation of tubular struc-
tures lined by uniform cuboidal epithelium extending into
the prostate chips. The ﬁndings were compared to those
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of the previous resection and the consensus was that this
represented further recurrence of the patient’s nephro-
genic adenoma. There was no evidence of malignancy.
Again, the patient’s hæmaturia was eﬀectively relieved
by this partial resection of the nephrogenic adenoma
and he remained well for a further 12 months. We
were contacted again by the patient’s General Prac-
titioner in September 2007 when his PSA had risen
to 6.1 ng/mL without ﬁnasteride from a previous
level of 1.9 mg/L on ﬁnasteride. The ﬁnasteride had
been stopped for unknown reasons. The patient also
described brief periods of frank hæmaturia over the
most recent 2 months period, lasting 3–4 days at a time
but without clots. His hæmoglobin remained stable at
13.1 g/dL.
And intravenous urogram and contrast CT of the
patient’s abdomen and pelvis revealed a giant hyper-
trophic prostate, measuring 11 cm × 10.5 cm × 8.5 cm
with a massive median lobe protruding into the bladder
(Figure 1). The pelvic tissue planes were clearly deﬁned,
reinforcing the benign nature of the patient’s pathology.
The reconstructed slice-by-slice volume was 460 cm3 at
this time, double the ultrasound volume of 215 mL mea-
sured just 2 years previously.
Most surprisingly, the patient reported only mini-
mal irritative LUTS (1× nocturia). A further TURP
was undertaken in December 2007 to ensure no malig-
nant change. Owing to the vascularity of the recur-
rent tumour, the patient experienced 4 days of pro-
longed post-operative hæmaturia requiring irrigation,
but without any signiﬁcant fall in his hæmoglobin
(12.3 g/dL).
Once again, the histology was compared against the 2
previous biopsy specimens, and deemed to be consistent
with the diagnosis of a recurrent nephrogenic adenoma of
the prostate gland.
The patient was recommenced on long-term ﬁnasteride,
but by early 2009 this was failing to control his increas-
ingly frequent episodes of macroscopic hæmaturia with
clots, now at least once every few weeks. The patient
was reluctant to undergo open suprapubic enucleation
of the giant adenoma, the standard surgical management
for this condition, but allowed us to perform a selective
prostatic artery embolisation in March of 2009, following
preliminary MR angiography.
Selective prostatic artery embolisation to control
hæmaturia
The procedure was performed under local anaesthesia
using a unilateral approach via a 5Fr catheter introduced
into the right common femoral artery. This gave access
to both internal iliac arteries allowing selective bilat-
eral catheterisation of the prostatic vessels with a coaxial
microcatheter.
Figure 1 IVU and CT Images Demonstrating the Intravesical
Projection of the Giant Benign Prostate with Nephrogenic
Adenoma. Image A - Intravenous Urogram from August 2007. Image
B - Volumetrically reconstructed CT image from October 2007.
The left prostatic vessels had a relatively small arborisa-
tion which was occluded with 500 μm polyphosphozene-
coated hydrogel microspheres (Embozene®, CeloNova
BioSciences) and an embolisation coil (VortX® 18 Vascular
Occlusion Coil, Boston Scientiﬁc). The right sided supply
was more profuse and was believed to supply the majority
of the prostatic lesion (Figure 2). This was occluded with
500 μm polyphosphozene-coated hydrogel microspheres
and 2 embolisation coils (MReye®, Cook Medical) with a
radiologically satisfactory outcome.
The patient was discharged home later that after-
noon. An MR examination 2-months post-procedure
demonstrated hæmorrhage in the posterior right side
of the prostate, the site of the most prominent vas-
culature, in keeping with a successful procedure. His
hæmaturia resolved following embolisation although he
described irritative LUTS of dribbling urge incontinence
3–4×/week and 2–3× nocturia in the early post-operative
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Figure 2 Selective Prostatic Artery Embolisation. Angiographic
image from the embolisation procedure undertaken in March 2009
demonstrating the dense arborisation of the right prostatic artery
supplying the large intravesical body of the giant prostate and
nephrogenic adenoma. Image taken immediately prior to
microsphere injection.
period. These symptoms soon resolved entirely on toltero-
dine XL 4mg OD.
Serial MR imaging over the intervening 36 months has
demonstrated no signiﬁcant change in the size of his giant
prostate, which still measures approximately 460 mL in
volume (Figure 3). However, he remains entirely asymp-
tomatic with no further hæmaturia or other LUTS on
ﬁnasteride 5 mg OD and tolterodine XL 4mg OD. His
most recent Qmax was 12.4mL/sec in January 2010, with a
residual volume of 65 mL, and his PSA remains low at 2.4
ng/mL as of January 2013.
Discussion
Giant prostatic hypertrophy (GPH) is a poorly explored
phenomenon, without large case series or deﬁnitive histo-
logical studies to deﬁne this as more than a rare subtype
of BPH where the gland exceeds 200 g in mass.
GPH commonly presents with obstructive lower uri-
nary tract symptoms and hæmaturia. Owing to the size of
the gland, deﬁnitive treatment usually requires suprapubic
prostatectomy [2][4], which our patient was reluctant to
undergo. As a result, we were required to manage his GPH
symptomatically with a combination of pharmacotherapy,
repeated de-bulking TURPs for biopsy and therapeutic
purposes, and ﬁnally selective prostatic artery embolisa-
tion for his recurrent hæmaturia, the ﬁrst such case in the
literature.
Whilst we understand that standard operative man-
agement of BPH would have had us deﬁnitively resect
our patient’s prostate at the operation in July 2002, this
was limited by a combination of a highly vascular gland,
prolonged operating time and the choice to use spinal
anæsthesia. Furthermore, prior to the development of
giant hypertrophy, the patient’s symptoms were predom-
inantly irritative rather than obstructive, as conﬁrmed by
the good pre-operative ﬂow result (Qmax of 14.4mL/sec)
(Figure 4). We presented the patient with the opportunity
for an early repeat TURP to complete the initial proce-
dure which he declined owing to subjective symptomatic
improvement.
By the time the patient required further transurethral
intervention, the combination of nephrogenic adenoma
and giant hypertrophy further complicated the proce-
dure and ruled out standard management techniques. Of
note, even at this stage the patient’s symptoms deﬁed
the common presentation for this condition and were
predominantly irritative with hæmaturia, rather than
obstructive.
Nephrogenic adenoma
Nephrogenic adenomas are believed to represent shed
renal tubular cells implanting into areas of damaged
urothelial integrity [7]. Predisposing factors are known to
include chronic inﬂammation, infection, calculi and uro-
logical surgery including TURP and renal transplantation
[9].
Most features of our patient’s history are typical for
recurrent nephrogenic adenoma. He was a middle-aged
male with an initial urothelial insult in the form of
a transurethral resection of the prostate in July 2002.
The interval between this initial transurethral resec-
tion and the diagnosis of nephrogenic adenoma was
35 months, and his two subsequent recurrence-free
intervals following TURP de-bulking were 14 months
each.
Our patient’s PSA has remained between 1.7ng/mL and
2.4 ng/mL whilst on ﬁnasteride, with a brief rise to 6.1
ng/mL in late 2007 when this was temporarily halted
(Figure 4). This reﬂects the benign nature of giant pro-
static hypertrophy and the low to zero PSA expression in
nephrogenic adenomas.
As in our case, macroscopic features consistent with
nephrogenic adenoma included papillary and/or ulcer-
ated lesions of the urinary epithelium which may
superﬁcially resemble prostatic adenocarcinoma. The
microscopic features of resemble remnants of embryonal
renal tissue, with small tubules located in the lamina pro-
pria and occasional papillary foci or thyroidisation. The
lining cells are often cuboidal without atypia or mitoses.
Nephrogenic adenomas also commonly express PAX2, a
key renal embryonal transcription factor, which has come
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Figure 3 Sequential Saggital T2 MR Imaging of the Patient’s Giant Prostate. Image A - MRI from September 2008 (6 months prior to
embolisation). Image B - MRI from April 2011 (25 months after embolisation). Note the minimal change in volume and signal density between the
two images.
to be recognised as a speciﬁc and sensitive diagnostic
marker for these lesions [10].
These histological features were present in our
patient, but unfortunately our unit did not stain
for PAX2 at the time, which would have served as
an interesting but ultimately unnecessary additional
piece of information in this case. For a thorough
review of the histology of nephrogenic adenoma, see
Kunju (2010) [6].
The largest case series of nephrogenic adenomas iso-
lated to the prostate gland itself include 26 patients
from The Johns Hopkins Hospital [11], and 8 cases
from The University of Texas MD anderson Cancer
Center [12]. Whilst the histological features described
in these cases match those found in our patient, there
have been no prior reports in the literature of nephro-
genic adenomas occurring in giant prostatic hypertro-
phy, nor their treatment by selective prostatic artery
embolisation.
Physiological role of PAX2
The nine PAX (paired homeobox) genes are a series
of transcription factors that are critical in orchestrat-
ing normal embryogenesis in animal species. Each one
appears to be expressed in a limited and speciﬁc range
of developing tissues, with PAX2 apparently responsible
Figure 4 Patient Timeline. Graphical representation of the patient’s treatment over 10 years from January 2001 – December 2010. The image
provides an overview of the patient’s Hæmoglobin (red), Uroﬂowmetry (blue) and PSA results (orange) along with the key events in his treatment
(Transrectal Biopsy, TURPs and Embolisation). Where multiple Hæmoglobin results were available for a given month, the lowest value was chosen to
represent the worst-case scenario.
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for eye, ear, central nervous system and urogenital tract
development [13].
Expression of PAX2 appears to be temporally and spa-
tially modulated in the embryonic kidney by the expres-
sion of the Wilms’ Tumour protein (WT-1) [14]. These
two factors coordinate to regulate the branching and
survival of the ureteric bud and the diﬀerentiation of
mesenchymal cells to epithelial cells [15] before PAX2
expression is then totally suppressed outside the collecting
system. Over-expression of PAX2 beyond embryogenesis
only appears to be seen in pathological conditions, includ-
ing renal cell carcinomas, polycystic kidney disease and
Wilms’ tumour.
However, and perhaps of greatest interest in our partic-
ular case, in vitro studies have demonstrated that PAX2
appears to be normally re-expressed in adult tubular cells
following ischæmia/reperfusion injury [13].
This could well explain why a transcription factor
whose expression beyond the renal collecting system nor-
mally terminates during embryogenesis appears to be
re-expressed in nephrogenic adenomas and lead to such
characteristic histological features - the shed tubular cells
are attempting to regenerate normal tubular tissues at
their site of implantation.
Certainly more work needs to be done to explore the
speciﬁc growth factor environment which allows nephro-
genic adenomas to take root and to reoccur despite mul-
tiple resections, but our particular case does suggest a
possible link between the nesting of nephrogenic ade-
noma precursor cells in our patient’s TURP-traumatised
prostate and the subsequent development of his giant
prostatic hypertrophy.
Management of refractory prostatic hæmaturia
Traditional management options for BPH-related LUTS
include pharmacotherapy (α-blockade and 5α-reductase
inhibition) and transurethral resection. Our patient
was managed quite eﬀectively on continuous 5α-
reductase blockade (ﬁnasteride) and 2 interim de-
bulking TURPs between September 2006 and March
2009, after which his hæmaturia became refractory to
pharmacotherapy.
Cases of TURP and/or fulguration-refractory gross
hæmaturia as experienced by our patient are more dif-
ﬁcult to manage, with only limited options available.
Intravesical chemo-cautery with alum, formalin or silver
nitrate have been described in the literature, along with
hydrostatic pressure or balloon tamponade [16]. Depend-
ing on the particular therapy selected, adverse eﬀects
can include allergic reactions, aluminium toxicity, bladder
ﬁbrosis and urethral stricturing caused by the instillation
agent, to renal impairment and bladder rupture. How-
ever, none of these reports speciﬁcally addressed giant
prostatic hypertrophy.
Selective prostatic artery embolisation
The use of selective internal iliac arterial embolisation
is in widespread use for the treatment of symptomatic
uterine leiomyomata. It has also been described for
the management of intractable hæmorrhage secondary
to advanced pelvic malignancies, with good long-term
outcomes [17].
There are however few studies exclusively reporting
on the management of refractory gross hæmorrhage of
prostatic origin by selective prostatic artery embolisation
(SPAE). The largest case series to date was published
in 2008 [18], involving 8 patients in total (6 with post-
radiotherapy prostatic adenocarcinoma, 2 with BPH) and
ascribing a 100% immediate cessation rate to SPAE fol-
lowing failure of conventional therapies. These beneﬁts
extended out to a median of 20 months follow-up in 6 of
the 8 patients (1.5–86.3 month range).
The series reported by Liguori et al. in 2010 did
include 15 patients with prostatic adenocarcinoma, but
did not break down their outcomes according to pri-
mary pathology. They did achieve an 83% immedi-
ate control rate following selective internal iliac artery
embolisation across all 44 patients in their study, but
at a mean follow-up interval of 10.5 months (1–97
month range), permanent control was only achieved in
19 (43%).
There are other single case reports in the English-
language literature speciﬁcally describing SPAE for pro-
static hæmorrhage refractory to other therapies, with
generally high levels of initial success, but listing them all
would not be useful here.
SPAE has also been employed for the primary manage-
ment of BPH without hæmaturia. A 2011 report by Pisco
et al. described 15 patients with symptomatic BPH treated
with SPAE who demonstrated moderate improvements
in IPSS and Qmax that were sustained at a mean of 7.9
months follow-up (3–12 month range). In this study how-
ever, there was a clinical failure rate of 28.6% (4 patients)
and one major complication of bladder wall ischaemia
[19].
Whereas all of these studies are limited by their short
follow-up periods, our case is the ﬁrst to demonstrate
the durable long-term results of SPAE in the treatment
of refractory hæmaturia and LUTS secondary to GPH
and nephrogenic adenoma. Our patient had recurrent
rapid prostatic re-growth over the 4 years from 2005–
2009, and despite 2 TURPs for debulking and symptom
control, his hæmaturia eventually became refractory
to pharmacotherapy with 5α-reductase inhibitors. 36
months following embolisation, we have found no fur-
ther increase in his prostatic volume on serial MRIs (but
also no reduction), no further episodes of hæmaturia
and no recurrence of his irritative LUTS or decline in
his Qmax.
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Conclusions
We have demonstrated that it is possible to manage irri-
tative LUTS and intermittent frank hæmaturia from the
giant hypertrophied prostate in the long term with a
combination of trans-urethral resections to de-bulk the
tumour, 5α-reductase blockade to reduce tumour vascu-
larity and ﬁnally selective prostatic artery embolisation to
control refractory hæmaturia when open enucleation is
not an option.
This case serves to promote the acceptability of selec-
tive prostatic artery embolisation as a safe, eﬀective and
durable treatment option for managing hæmorrhagic pro-
static pathologies, particularly in patients for whom other
forms of therapy are not possible.
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